ACAD News
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
Zacks
European Commission Approves DAYBU (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and...
Business Wire
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.
Zacks
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?
Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Zacks
Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?
Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations
As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.
Zacks
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales
Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.
Zacks
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +200.00% and +4.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks